X
All Data
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): Eptinezumab
Therapeutic Area: Neurology Product Name: Vyepti
Highest Development Status: Approved Product Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable June 15, 2021
Details:
Patients receiving VYEPTI reported a median time to headache pain freedom of 4 hours vs. 9 hours among those who received placebo, and a median time of 2 hours to the absence of their MBS vs. 3 hours with placebo.
Active Pharmaceutical Ingredients
Finished Drug Formulations
Prices
Excipients
Services
Marketplace
News Type
